Compare ProShares Ultra Semiconductors (USD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra Semiconductors vs State Street SPDR S&P Biotech ETF — how do they compare? ProShares Ultra Semiconductors trades at $90.2, while State Street SPDR S&P Biotech ETF trades at $154.37. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, ProShares Ultra Semiconductors nearer its low. Which is the better fit depends on your goals.
| USD | XBI | |
|---|---|---|
Sector | Leveraged / Inverse | Broad Market / Factor |
52-Week High | $113.53 | $164.28 |
52-Week Low | $39.58 | $85.16 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
USD stock trades at $83.24, up 1.19% with a bearish technical signal from moving averages. The company shows limited financial data availability, with key valuation and profitability ratios not provided. Recent corporate actions include a future dividend announcement for June 2026. Technical indicators show neutral oscillators but bearish momentum signals with support at $82 and resistance at $86.
The outlook remains cautious due to bearish technical indicators and incomplete fundamental data. Investment opportunities depend on forthcoming financial disclosures, while risks include market volatility and the stock's current technical weakness. The neutral sentiment from oscillators suggests potential stabilization near current levels.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
